quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:21:17·64d
ANALYSTRating
BioCryst Pharmaceuticals Inc. logo

Evercore ISI resumed coverage on BioCryst Pharma with a new price target

BCRX· BioCryst Pharmaceuticals Inc.
Health Care
Original source

Companies

  • BCRX
    BioCryst Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 18UpdateEvercore ISI$17.00
  • Oct 15UpdateTD Cowen$30.00
  • Oct 1UpdateEvercore ISI$8.00
  • Apr 29UpdateCantor Fitzgerald$20.00
  • Feb 25UpdateWedbush$15.00
  • Nov 20UpdateJP Morgan$10.00

Related

  • SEC14h
    SEC Form DEFA14A filed by BioCryst Pharmaceuticals Inc.
  • SEC14h
    SEC Form DEF 14A filed by BioCryst Pharmaceuticals Inc.
  • PR8d
    BioCryst to Report First Quarter 2026 Financial Results on May 6
  • INSIDER16d
    SEC Form 4 filed by Menon Sandeep
  • INSIDER16d
    SEC Form 3 filed by new insider Menon Sandeep
  • PR17d
    BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
  • PR20d
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by BioCryst Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022